πŸ“‘ Clinical compound research updates β€” regulatory updates, new compound profiles, COA alerts.

⚠️ FDA PCAC: -- days left

No spam. Unsubscribe anytime. 7 peptides under review β€” see what's at stake β†’

πŸ”¬ Free Tools

Put this research to work

7 free research tools built around exactly this kind of compound data. No paywall, no credit card.

πŸ’‰ Peptide Calculator πŸ“ HGH Calculator 🩸 Bloodwork Interpreter βš—οΈ Interaction Checker πŸ“‹ COA Analyzer πŸ“… Protocol Builder
Explore All Free Tools β†’
Research Library β€Ί Medicine Library β€Ί Levothyroxine / T3-T4
Hormone Thyroid Research Use Only

Levothyroxine / T3-T4 Thyroid Hormones

The most prescribed medication in the United States β€” thyroid hormone replacement underpins metabolic rate, thermogenesis, cardiac function, and anabolic signaling. In research contexts, T3 (liothyronine) is studied for interactions with the GH/IGF-1 axis and AAS protocols, while T4-to-T3 conversion dynamics are critical for optimizing thyroid status monitoring.

T4 Half-life: ~7 days
T3 Half-life: ~1 day
Route: Oral
Brands (T4): Synthroid, Levoxyl, Tirosint
Brands (T3): Cytomel
⚠️ Research Use Only. This profile is for educational and research purposes only. Levothyroxine and liothyronine are prescription medications. This is not medical advice. T3 use without proper baseline monitoring carries cardiac risk. Consult a licensed healthcare provider for any clinical application.
<\!-- Main Content -->
<\!-- 1. Overview -->
πŸ”¬

Overview

Levothyroxine (T4) is the primary thyroid hormone replacement compound and the most commonly prescribed medication in the United States. It treats hypothyroidism β€” a condition affecting an estimated 20 million Americans β€” and is also used at suppressive doses in thyroid cancer management.

The thyroid hormone system involves two principal hormones: T4 (thyroxine / levothyroxine) β€” the predominant secretory product of the thyroid gland, serving primarily as a prohormone β€” and T3 (triiodothyronine / liothyronine) β€” the biologically active form that exerts most of the downstream metabolic effects. The peripheral conversion of T4 to T3 via deiodinase enzymes is a critical regulatory step that can be disrupted by illness, nutritional deficiencies, certain medications, and β€” importantly for research contexts β€” anabolic compound use.

Brand names: Synthroid, Levoxyl, and Tirosint (T4); Cytomel (T3 / liothyronine); Armour Thyroid and Nature-Throid (desiccated thyroid β€” combined T3/T4 from porcine thyroid gland).

In biohacking and AAS research contexts, T3 (liothyronine) is specifically studied for its direct metabolic and thermogenic effects, its interaction with the growth hormone/IGF-1 axis, and its potential to counter AAS-induced metabolic suppression or to enhance the anabolic environment by optimizing thyroid status during research protocols.

<\!-- 2. Mechanism -->
⚑

Mechanism of Action

Understanding the T4-to-T3 conversion pathway is essential for interpreting thyroid research and bloodwork:

T4 Prohormone Conversion Pathway
β†’Thyroid gland secretes predominantly T4 (thyroxine) β€” the prohormone
β†’Peripheral tissues convert T4 β†’ T3 via deiodinase enzymes (DIO1 in liver/kidney; DIO2 in brain/pituitary/muscle)
β†’T3 enters cell nuclei, binds thyroid hormone receptors (TRΞ±, TRΞ²)
β†’Nuclear receptor complex regulates transcription of hundreds of metabolic genes
T3 Metabolic Effects (Active Hormone)
β†’Upregulates mitochondrial oxidative phosphorylation β†’ increases basal metabolic rate (BMR)
β†’Increases thermogenesis via uncoupling protein (UCP1) expression in brown adipose tissue
β†’Regulates cardiac rate and contractility (chronotropic + inotropic effects)
β†’Modulates cholesterol metabolism β€” hypothyroidism classically raises LDL
β†’Regulates protein synthesis and degradation β€” interacts with IGF-1 and GH signaling
GH/IGF-1 Axis Interaction
β†’Growth hormone upregulates DIO2 (deiodinase type 2) β†’ increases T4-to-T3 conversion
β†’Adequate T3 is required for normal GH receptor sensitivity and IGF-1 production
β†’Hypothyroid states reduce GH secretion and IGF-1 levels β€” optimizing thyroid status can enhance GH axis function

Reverse T3 (rT3): T4 can also be converted to reverse T3 β€” an inactive metabolite that competes with T3 at receptor binding sites. Elevated rT3 (seen in illness, stress, caloric restriction, and AAS use) effectively reduces thyroid hormone bioavailability even when total T3 levels appear normal. This is why Free T3 and rT3 panels matter beyond TSH alone.

πŸ“

Clinical Protocol Context

Research Disclaimer: The following reflects published clinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.

Levothyroxine (synthetic T4) is the most prescribed endocrine medication worldwide and the standard of care for hypothyroidism. The ATA Guidelines (Jonklaas et al., 2014, Thyroid) provide the definitive treatment framework. The Colorado Thyroid Disease Prevalence Study (Canaris et al., 2000, Arch Intern Med) established the population-level prevalence of thyroid dysfunction. Absorption pharmacokinetics have been characterized by Benvenga et al. (2001), demonstrating significant food, medication, and supplement interactions that affect dosing protocols.

Dosing Ranges from Published Studies
Hypothyroidism 1.6 mcg/kg/day (full replacement); starting 25–50 mcg/day in elderly or cardiac patients. Typical maintenance 75–150 mcg/day. Titrate by 12.5–25 mcg every 6–8 weeks based on TSH. Jonklaas J et al. (2014, Thyroid).
TSH Suppression 2–2.5 mcg/kg/day for differentiated thyroid cancer. Target TSH <0.1 mIU/L (high-risk) or 0.1–0.5 (low-risk). Haugen BR et al. (2016, Thyroid β€” ATA thyroid cancer guidelines).
Myxedema Coma 200–500 mcg IV loading dose, then 50–100 mcg IV daily. Life-threatening emergency requiring ICU. IV T3 often co-administered. Kwaku MP & Burman KD (2007, Endocrinol Metab Clin North Am).
Administration Routes Studied
Oral 25–300 mcg tablets (multiple brands). Take on empty stomach 30–60 minutes before breakfast (or at bedtime β‰₯3 hours after last meal). Calcium, iron, PPIs, and coffee reduce absorption 20–40%. Brand-to-generic switching can alter bioavailability by 12–25%. Benvenga S et al. (2001, J Clin Endocrinol Metab).
IV 40–80% of oral dose when converting. Used in myxedema coma or NPO patients. Onset of action within hours for metabolic effects.
Oral liquid (Tirosint-SOL) 13 strengths (13–200 mcg). Gelatin-free, dye-free. Improved absorption consistency in patients with GI malabsorption or concurrent acid-suppressive therapy. Vita R et al. (2014, Endocrine).
Study Durations & Timelines
4–6 Weeks TSH response measurable. Standard interval for dose adjustment. Half-life of T4 is ~7 days β€” steady-state requires 5 half-lives (35 days). Do not recheck TSH before 6 weeks post-dose change.
3–6 Months Full clinical response for most symptoms. Energy, weight, hair growth, and cold intolerance improve gradually. Some symptoms (hair regrowth, cognitive clarity) may take 6+ months.
Annual TSH monitoring annually once stable. More frequent if pregnant (TSH every 4 weeks in first trimester β€” requirements increase 25–50%). Bone density in postmenopausal women on suppressive doses. Canaris GJ et al. (2000, Arch Intern Med).
Bloodwork Monitoring from Clinical Protocols

TSH is the primary monitoring parameter β€” measured at baseline, 6–8 weeks after any dose change, then annually once stable. Free T4 measured concurrently to distinguish central from primary hypothyroidism and confirm adequate replacement. Free T3 not routinely recommended per ATA guidelines but useful if symptoms persist despite normal TSH/FT4. TPO antibodies at diagnosis for etiology (Hashimoto's). Lipid panel at baseline and 3–6 months (hypothyroidism causes reversible hypercholesterolemia). Bone density every 1–2 years in postmenopausal women on suppressive doses (TSH <0.1 accelerates bone loss). Pregnancy: TSH every 4 weeks through week 20, then at 30 weeks β€” levothyroxine dose typically increases 25–50%. Drug interaction monitoring: calcium, iron supplements, and PPIs must be separated by β‰₯4 hours from levothyroxine dose.

Key References: Jonklaas J et al. (2014). Guidelines for the treatment of hypothyroidism: prepared by the ATA task force on thyroid hormone replacement. Thyroid. Β· Canaris GJ et al. (2000). The Colorado thyroid disease prevalence study. Arch Intern Med. Β· Benvenga S et al. (2001). Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. Β· Haugen BR et al. (2016). 2015 ATA management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid.

πŸ’‰

Dosing Frameworks

Levothyroxine (T4) β€” Replacement Dosing:

ContextDose / Protocol
Full replacement (complete hypothyroid)1.6–1.8 mcg/kg/day
Subclinical / partial β€” starting dose25–50 mcg/day, titrate up
Titration intervalIncrease by 25 mcg every 6–8 weeks, guided by TSH
TSH suppression (thyroid cancer)TSH target <0.1 β€” requires specialist monitoring
TimingEmpty stomach, 30–60 min before food; avoid within 4 hrs of calcium, iron, PPIs

Liothyronine (T3 / Cytomel) β€” Research Dosing:

ContextDose / Protocol
Clinical hypothyroid (T3 component)25–50 mcg/day, split into 2–3 doses (short half-life)
AAS/research contexts (low dose)12.5–25 mcg/day β€” to counter AAS-associated metabolic suppression
Combination T3/T4 (desiccated)Armour Thyroid β€” ratio 1:4 T3:T4 (porcine); dose guided by weight and labs
Titration cautionT3 has rapid onset and cardiac effects β€” never increase dose rapidly
T3 Timing Note
T3's short half-life (~24 hours vs. T4's ~7 days) means it requires multiple daily dosing and does not have the stable blood levels of T4. Some researchers prefer morning and noon dosing to avoid potential sleep disruption from late-day stimulatory effects. T4's 7-day half-life means once-daily dosing is sufficient and levels are highly stable.
<\!-- 4. Bloodwork -->
🩸

Bloodwork & Monitoring

Thyroid monitoring requires a multi-marker panel β€” TSH alone is insufficient for subjects on T4-only therapy who remain symptomatic, and is inadequate for AAS research contexts where TBG and rT3 dynamics alter interpretation.

Primary Thyroid Panel

TSH Free T4 Free T3 Reverse T3 (rT3)

TSH Interpretation: High TSH = undertreated (thyroid is working hard); Low TSH = over-treated or suppressed. Target for most replacement is TSH 0.5–2.0 mIU/L for symptom relief. Below 0.1 indicates suppression (only appropriate for thyroid cancer protocols β€” elevated cardiac and bone risk).

Baseline & Autoimmune Assessment

TPO Antibodies Anti-TG Antibodies

Thyroid peroxidase (TPO) and thyroglobulin (TG) antibodies identify autoimmune etiology (Hashimoto's thyroiditis) β€” important for prognosis and dose stability expectations.

Cardiovascular & Metabolic Monitoring

Lipid Panel Heart Rate (resting) Bone Density (long-term suppressive dosing)
AAS Context β€” TBG and rT3 Shifts
Testosterone and other androgens decrease thyroid-binding globulin (TBG), which transiently increases free T3 and free T4 levels. Estrogens have the opposite effect (increase TBG). When interpreting thyroid labs in subjects using AAS, always use free (not total) T3 and T4 measurements β€” TBG changes make total thyroid hormone levels unreliable in this population. Also monitor rT3 β€” AAS use can elevate rT3, reducing effective T3 bioavailability.
<\!-- 5. Side Effects -->
⚠️

Side Effects & Risk Profile

Side effects are essentially a spectrum of hyperthyroid or hypothyroid symptoms depending on whether dosing is excessive or insufficient:

  • Over-dose
    Cardiovascular β€” Palpitations, Tachycardia, AF Risk β€” The most clinically significant risk of excess thyroid hormone. Atrial fibrillation risk is meaningfully elevated when TSH is suppressed below 0.1 mIU/L, particularly in subjects over 60. Even subclinical hyperthyroidism (TSH 0.1–0.4) increases AF risk in older populations.
  • Over-dose
    Systemic Hyperthyroid Symptoms β€” Heat intolerance, excessive sweating, unintentional weight loss, diarrhea, anxiety, tremor, insomnia, and fatigue. These indicate the dose is too high and must be reduced before complications develop.
  • Chronic
    Bone Loss β€” Chronic excess thyroid hormone (suppressed TSH) accelerates bone turnover and reduces bone mineral density. Fracture risk increases with long-term suppressive dosing. DEXA monitoring is indicated for subjects on suppressive protocols.
  • Under-dose
    Hypothyroid Symptom Persistence β€” Fatigue, weight gain, cold intolerance, constipation, depression, cognitive slowing, bradycardia, dry skin, hair thinning, and dyslipidemia (elevated LDL). Indicates undertreated or undertreated hypothyroidism.
  • T3 Specific
    Narrow Therapeutic Window (T3) β€” Liothyronine's short half-life and rapid onset mean symptoms of excess appear quickly and sharply. Titrate T3 doses conservatively. Dose-dumping risk with rapid escalation is higher than with T4.
<\!-- 6. Drug Interactions -->
πŸ’Š

Drug & Compound Interactions

Testosterone / AAS β€” TBG Reduction
Androgens (testosterone and most AAS) decrease thyroid-binding globulin (TBG). This transiently increases free T3 and free T4 levels. Estrogens have the opposite effect β€” oral estrogens increase TBG, potentially reducing free thyroid hormone availability. Always use free hormone measurements in AAS research subjects. Thyroid dose adjustments may be needed when AAS protocols change significantly.
Growth Hormone Peptides (GHRH / GHSs)
GH upregulates DIO2 (type 2 deiodinase), increasing peripheral T4-to-T3 conversion. This means GH use can shift thyroid status in hypothyroid subjects on T4-only therapy, potentially requiring dose adjustments. Monitor Free T3 closely when initiating or changing GH peptide protocols alongside T4 replacement. Conversely, adequate thyroid status is required for normal GH receptor sensitivity and IGF-1 production.
Absorption Interactions (Critical)
Calcium carbonate, calcium citrate, ferrous sulfate (iron), proton pump inhibitors (PPIs), cholestyramine, and antacids containing aluminum/magnesium all significantly reduce levothyroxine absorption from the GI tract. These must be taken at least 4 hours apart from levothyroxine. Even high-calcium foods (dairy) can affect absorption if consumed at the same time. Inconsistent separation is a common cause of erratic TSH levels despite stable dosing.
Warfarin / Anticoagulants
Thyroid hormones increase sensitivity to warfarin by accelerating clotting factor catabolism. Starting or increasing thyroid hormone dose in a warfarin-treated subject requires INR monitoring and potential warfarin dose reduction. The effect is proportional to the degree of thyroid hormone change.
Metformin
No direct pharmacokinetic interaction between Metformin and levothyroxine. However, metabolic pathway synergy exists: optimizing thyroid status reduces the insulin resistance component of hypothyroidism, which can work complementarily with Metformin's insulin-sensitizing effects in metabolically compromised research subjects.
Selective Beta-Blockers (Propranolol)
Propranolol inhibits peripheral T4-to-T3 conversion and is sometimes used short-term to manage hyperthyroid symptoms (especially cardiovascular). Relevant research context: in subjects using T3 who develop tachycardia or palpitations, beta-blockers may mask cardiac symptoms while the underlying thyroid excess persists.
<\!-- 7. Harm Reduction -->
πŸ›‘οΈ

Harm Reduction

T3 Cardiac Risk β€” Titrate Conservatively
T3 (liothyronine) has direct, rapid cardiac effects β€” increased heart rate, contractility, and cardiac output. Never increase T3 doses rapidly. Start at the lowest effective dose (12.5 mcg) and titrate slowly. Palpitations or resting heart rate above 90–95 bpm is a signal to reduce the dose, not push through. Abrupt high-dose T3 initiation without baseline testing is high-risk.
TSH Alone is Not Enough
TSH is the primary monitoring tool but misses important information in research contexts. A "normal" TSH with low Free T3 indicates a conversion problem. Elevated rT3 with normal TSH indicates functional thyroid hormone insufficiency at the tissue level. Get the full panel: TSH + Free T4 + Free T3 + rT3 at minimum for research protocol monitoring.

Absorption Protocol: Take levothyroxine consistently on an empty stomach, 30–60 minutes before any food, coffee, or supplements. Separate from calcium, iron, and PPIs by at least 4 hours. Tirosint (gel capsule formulation) has improved absorption consistency and is an option for subjects with variable GI absorption.

AAS Protocol Monitoring: Monitor thyroid panel at each bloodwork check during AAS protocols β€” the TBG changes induced by androgens can shift free thyroid hormone levels significantly. Dose adjustments may be needed when starting, cycling off, or changing AAS compound selection.

T3 Discontinuation β€” Taper, Don't Stop Abruptly
Exogenous T3 suppresses endogenous thyroid production rapidly (via TSH feedback suppression). Abrupt discontinuation after a T3 protocol can result in a transient hypothyroid state while the HPT axis recovers. Taper T3 doses gradually β€” reduce by 12.5 mcg every 1–2 weeks β€” to allow the HPT axis to restore normal feedback signaling. Monitor TSH 4–6 weeks after discontinuation to confirm recovery.

Do Not Start T3 Without Baseline Testing: Initiating exogenous T3 in a euthyroid subject suppresses natural T3 production immediately. If not confirmed hypothyroid, you are running a T3-excess state. Confirm baseline TSH, Free T3, and Free T4 before any T3 research protocol.

<\!-- 8. Research & Literature -->
πŸ“š

Research & Literature

  • ATA Guidelines β€” American Thyroid Association
    Comprehensive clinical guidelines for hypothyroidism diagnosis and management, including T3 combination therapy, TSH targets, and monitoring standards. The ATA guidelines on combination T3/T4 therapy represent the most evidence-based framework for thyroid hormone research protocols.
  • TRUST Trial β€” Thyroid Hormone Replacement for Older Adults
    A large RCT studying treatment of subclinical hypothyroidism in adults over 65. Found limited symptomatic benefit from levothyroxine in older adults with subclinical hypothyroidism, raising questions about the universal treat-to-TSH-normal approach in aging populations.
  • Wiersinga et al. β€” T3/T4 Combination Therapy
    Systematic reviews on the evidence for and against adding T3 to T4-only thyroid hormone replacement. Remains a clinically debated area β€” some patients remain symptomatic on T4 alone despite normal TSH, potentially due to impaired T4-to-T3 conversion.
  • Colorado Thyroid Disease Prevalence Study
    Landmark epidemiological study establishing prevalence of thyroid dysfunction β€” approximately 10% of the population has abnormal TSH, with clinical hypothyroidism affecting 4–5% and subclinical hypothyroidism up to 9%. The foundational prevalence data for thyroid disease research.
  • Bianco et al. β€” Peripheral T3 Production and Deiodinase Enzymology
    Comprehensive work on how peripheral tissues regulate T3 availability via deiodinase isoforms (DIO1, DIO2, DIO3). Particularly relevant for understanding why serum T3 may not reflect tissue T3 levels in all contexts β€” including AAS and illness states.
  • MΓΌller & Kern β€” GH and Thyroid Hormone Interactions
    Research on the bi-directional interaction between growth hormone axis and thyroid hormone status. GH upregulates DIO2-mediated T3 production; conversely, hypothyroidism reduces GH secretion and IGF-1 levels. Key mechanistic framework for understanding GH peptide and thyroid interactions in research protocols.
<\!-- /cpd-main --> <\!-- Sidebar -->
<\!-- /compound-content-layout -->